MeiraGTx Secures Up to $400M Strategic Investment from Oberland Capital, Repays Existing Debt

summarizeSummary

MeiraGTx announced a strategic investment of up to $400 million from Oberland Capital, including up to $375 million in non-dilutive royalty funding and a $25 million equity component, while simultaneously repaying its existing debt with Perceptive Credit Holdings III, LP.

check_boxKey Events · Financing and Capital Events · MGTX

• Secured Up to $375M in Royalty Notes

  MeiraGTx entered into a Royalty Note Purchase Agreement with Oberland Capital for up to $375 million. An initial $125 million was funded on June 30, 2026, with an additional $25 million due July 17, 2026. Further tranches of $50 million each are contingent on positive Phase 2 AQUAx2 data for AAV-hAQP1 and regulatory approvals for bota-vec and AAV-hAQP1. An additional $100 million is available upon mutual agreement. Purchasers will receive capped payments equal to 1.95% of global net sales of AAV-AIPL1, AAV-hAQP1, and bota-vec, with obligations secured by product-related assets.

• Received $10M Equity Investment with Option for More

  As part of the Oberland Capital deal, MeiraGTx issued 950,570 ordinary shares for $10.0 million at a price of $10.52 per share (the 30-day volume-weighted average price prior to signing). Investors also have the option to acquire an additional $15.0 million in ordinary shares. These shares are subject to a 180-day lock-up period and a beneficial ownership limit of 4.9% (or up to 19.9% with notice).

• Repaid Existing Debt

  The company fully redeemed all outstanding principal amounts under its Amended and Restated Notes Purchase Agreement with Perceptive Credit Holdings III, LP, with no early termination penalties. This new financing package replaces the previous debt.

• Pipeline Validation and Extended Runway

  This comprehensive financing package provides significant capital, with a large portion being non-dilutive equity-wise, to support the development and potential commercialization of MeiraGTx's late-stage programs. The conditional funding tranches tied to clinical and regulatory milestones for AAV-hAQP1 and bota-vec demonstrate external validation of the company's pipeline.

auto_awesomeAnalysis · MGTX · Life Sciences

MeiraGTx has secured a substantial financing package, primarily non-dilutive royalty funding, which significantly strengthens its balance sheet and extends its cash runway. The deal includes performance-based tranches tied to key pipeline milestones, signaling strong investor confidence in the company's late-stage gene therapy programs. This capital infusion, coupled with the repayment of existing debt, provides critical resources for advancing its product candidates towards commercialization.